Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

التفاصيل البيبلوغرافية
العنوان: Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
المؤلفون: Magda Barinova, Bohuslav Melichar, Karolina Hurdalkova, Martin Svaton, Jiri Blazek, Lenka Jakubíková, M. Černovská, Michal Jirousek, Daniel Krejci, Jana Skrickova, Milada Zemanova, J. Krejčí, Petra Zemanova, Michal Hrnčiarik, Ondrej Bilek, Ondrej Fischer, Juraj Kultan
المصدر: Anticancer Research. 40:2209-2217
بيانات النشر: Anticancer Research USA Inc., 2020.
سنة النشر: 2020
مصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Kaplan-Meier Estimate, 03 medical and health sciences, Route of administration, 0302 clinical medicine, Adrenal Cortex Hormones, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Outcome Assessment, Health Care, Humans, Medicine, Lung cancer, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Univariate analysis, business.industry, Probiotics, Anti-Inflammatory Agents, Non-Steroidal, Cancer, Proton Pump Inhibitors, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Metformin, Anti-Bacterial Agents, 3. Good health, Nivolumab, 030220 oncology & carcinogenesis, Concomitant, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, medicine.drug
الوصف: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment. © 2020 International Institute of Anticancer Research. All rights reserved.
تدمد: 1791-7530
0250-7005
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4470fb7f205d242846a16e4aa39f0ebb
https://doi.org/10.21873/anticanres.14182
رقم الأكسشن: edsair.doi.dedup.....4470fb7f205d242846a16e4aa39f0ebb
قاعدة البيانات: OpenAIRE